Clinical trial NCT06088043: A Study About How Well TAK-279 Works and Its Safety in Participants With Moderate-to-severe Plaque Psoriasis During 52 Weeks of Treatment
Official title: A Phase 3, Randomized, Multicenter, Double-Blind, Placebo- and Active Comparator-Controlled Study to Evaluate the Efficacy, Safety, and Tolerability of TAK-279 in Subjects With Moderate-to-Severe Plaque Psoriasis
Study type: INTERVENTIONAL
Overall status: ACTIVE_NOT_RECRUITING
Phase: PHASE3
Conditions: Plaque Psoriasis
Keywords: Drug Therapy
Latitude Psoriasis 1, Latitude Research Program
Lead sponsor: Takeda
Sponsor class: INDUSTRY
First posted: 2023-10-18
Enrollment: 693
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: TREATMENT

Brief summary: The main aim of this study is to show how well TAK-279 reduces the skin plaques compared to placebo, in participants with moderate-to-severe plaque psoriasis. Participants will be assigned to one of the 3 study treatments (TAK-279, apremilast (an approved treatment), or a placebo). Participants will be in the study for up to 61 weeks.

Detailed description: The drug being tested in this study is called TAK-279. TAK-279 is being tested to treat people with moderate to severe plaque psoriasis.

The study will enroll approximately 600 patients. Participants will be randomly assigned (by chance, like flipping a coin) to one of the following treatment groups in a ratio of 3:1:1 to receive TAK-279, placebo, or apremilast which will remain undisclosed to the participant and study doctor during the study (unless there is an urgent medical need):

1. TAK-279
2. Placebo
3. Apremilast

This multi-center trial will be conducted worldwide. Participants will go through a screening process to make sure they meet the rules for taking part in the study. This will take up to 35 days. If participants meet the study rules, they will be treated for up to 52 weeks (1 year). There will be a safety follow-up visit 4 weeks after their last day of treatment.

Eligibility criteria: Inclusion Criteria:

1. Plaque psoriasis for at least 6 months.
2. Moderate to severe disease.
3. Candidate for phototherapy or systemic therapy.

Exclusion Criteria:

1. Other forms of psoriasis.
2. History of recent infection.
3. Prior exposure to TAK-279 or active comparator.

Other protocol defined inclusion/exclusion criteria apply.

Primary outcomes:
measure: Percentage of Participants Achieving a Static Physician's Global Assessment (sPGA) of Clear (0) or Almost Clear (1) with a >=2-Point Decrease from Baseline at Week 16 Comparing TAK-279 Against Placebo
timeFrame: Baseline, Week 16
measure: Percentage of Participants Achieving >=75% Improvement from Baseline in Psoriasis Area and Severity Index (PASI) Score (PASI-75 Response) at Week 16 Comparing TAK-279 Against Placebo
timeFrame: Baseline, Week 16
Secondary outcomes:
measure: Percentage of Participants Achieving 90% Improvement from Baseline in PASI (PASI-90 Response) at Week 16 Comparing TAK-279 Against Placebo
timeFrame: Baseline, Week 16
measure: Percentage of Participants Achieving an sPGA of Clear (0) at Week 16 Comparing TAK-279 Against Placebo
timeFrame: Week 16
measure: Percentage of Participants Achieving PASI-100 at Week 16 Comparing TAK-279 Against Placebo
timeFrame: Week 16
measure: Percentage of Participants Achieving a Scalp-specific Physician's Global Assessment (ssPGA) of Clear (0) or Almost Clear (1) with a >=2-Point Decrease from Baseline at Week 16 Comparing TAK-279 Against Placebo
timeFrame: Baseline and Week 16
measure: Percentage of Participants with a Baseline Dermatology Life Quality Index (DLQI) Score >=2 who Achieve DLQI Score of 0 or 1 at Week 16 Comparing TAK-279 Against Placebo
timeFrame: Week 16
measure: Percentage of Participants with a Baseline Psoriasis Symptoms and Signs Diary (PSSD) >=1 who Achieve Weekly Mean PSSD Symptom Score of 0 at Week 16 Comparing TAK-279 Against Placebo
timeFrame: Week 16
measure: Change from Baseline in Nail Psoriasis Severity Index (NAPSI) at Week 16 Among Participants with Nail Involvement at Baseline Comparing TAK-279 Against Placebo
timeFrame: Baseline and Week 16
measure: Change from Baseline in Body Surface Area (BSA) Affected by Psoriasis at Week 16 Comparing TAK-279 Against Placebo
timeFrame: Baseline and Week 16
measure: Percent Change from Baseline in Body Surface Area (BSA) Affected by Psoriasis at Week 16 Comparing TAK-279 Against Placebo
timeFrame: Baseline and Week 16
measure: Percentage of Participants Achieving a Physician's Global Assessment (PGA) of the Hands and/or Feet of Clear (0) or Almost Clear (1) with a >=2-Point Decrease From Baseline at Week 16 Comparing TAK-279 Against Placebo
timeFrame: Baseline and Week 16
measure: Change from Baseline in DLQI at Week 16 Comparing TAK-279 Against Placebo
timeFrame: Baseline and Week 16
measure: Change from Baseline in the Short Form-36 Health Survey (SF-36) Version 2 Scores at Week 16 Comparing TAK-279 Against Placebo
timeFrame: Baseline and Week 16
measure: Change from Baseline in the EuroQoL 5-Dimension 5-level Questionnaire (EQ-5D-5L) Scores at Week 16 Comparing TAK-279 Against Placebo
timeFrame: Baseline and Week 16
measure: Change in Work Productivity and Activity Impairment-Psoriasis (WPAI-PSO) Questionnaire Scores at Week 16 Comparing TAK-279 Against Placebo
timeFrame: Week 16
measure: Percentage of Participants Achieving an sPGA of Clear (0) or Almost Clear (1) with a >=2-Point Decrease from Baseline at Week 16 Comparing TAK-279 Against Apremilast
timeFrame: Baseline and Week 16
measure: Percentage of Participants Achieving PASI-75 at Week 16 Comparing TAK-279 Against Apremilast
timeFrame: Week 16
measure: Percentage of Participants Achieving PASI-90 at Week 16 Comparing TAK-279 Against Apremilast
timeFrame: Week 16
measure: Percentage of Participants Achieving an sPGA of Clear (0) or Almost Clear (1) with a >=2-Point Decrease from Baseline at Week 24 Comparing TAK-279 Against Apremilast
timeFrame: Baseline and Week 24
measure: Percentage of Participants Achieving PASI-75 at Week 24 Comparing TAK-279 Against Apremilast
timeFrame: Week 24
measure: Percentage of Participants Achieving PASI-90 at Week 24 Comparing TAK-279 Against Apremilast
timeFrame: Week 24
measure: Change from Baseline in Weekly Mean PSSD Symptom Score at Week 16 Comparing TAK-279 Against Apremilast
timeFrame: Baseline and Week 16
measure: Percentage of Participants Achieving an ssPGA of Clear (0) or Almost Clear (1) with a >=2-Point Decrease from Baseline at Week 16 Comparing TAK-279 Against Apremilast
timeFrame: Week 16
measure: Percentage of Participants Achieving PASI-100 at Week 16 Comparing TAK-279 Against Apremilast
timeFrame: Week 16
measure: Percentage of Participants Achieving PASI-100 at Week 24 Comparing TAK-279 Against Apremilast
timeFrame: Week 24
measure: Percentage of Participants Achieving an sPGA of Clear (0) at Week 16 Comparing TAK-279 Against Apremilast
timeFrame: Week 16
measure: Percentage of Participants with a Baseline DLQI Score >=2 who Achieve DLQI Score of 0/1 at Week 16 Comparing TAK-279 Against Apremilast
timeFrame: Week 16
measure: Percentage of Participants with a Baseline PSSD >=1 who Achieve a Weekly Mean PSSD Symptom Score of 0 at Week 16 Comparing TAK-279 Against Apremilast
timeFrame: Week 16
measure: Change from Baseline in NAPSI, Among Participants with Nail Involvement at Baseline at Weeks 16 and 24 Comparing TAK-279 Against Apremilast
timeFrame: Baseline, Weeks 16 and 24
measure: Percentage of Participants Achieving an ssPGA of Clear (0) or Almost Clear (1) with a >=2-Point Decrease from Baseline at Week 24 Comparing TAK-279 Against Apremilast
timeFrame: Baseline and Week 24
measure: Change from Baseline in DLQI at Weeks 16 and 24 Comparing TAK-279 Against Apremilast
timeFrame: Baseline, Weeks 16 and 24
measure: Change from Baseline in BSA Affected by Psoriasis at Weeks 16 and 24 Comparing TAK-279 Against Apremilast
timeFrame: Baseline, Weeks 16 and 24
measure: Percent Change from Baseline in BSA Affected by Psoriasis at Weeks 16 and 24 Comparing TAK-279 Against Apremilast
timeFrame: Baseline, Weeks 16 and 24
measure: Percentage of Participants Achieving an sPGA of Clear (0) at Week 24 Comparing TAK-279 Against Apremilast
timeFrame: Week 24
measure: Percentage of Participants with a Baseline DLQI Score >=2 who Achieve a DLQI Score of 0/1 at Week 24 Comparing TAK-279 Against Apremilast
timeFrame: Week 24
measure: Percentage of Participants with a Baseline PSSD >=1 who Achieve a Weekly Mean PSSD Symptom Score of 0 at Week 24 Comparing TAK-279 Against Apremilast
timeFrame: Week 24
measure: Change from Baseline in ssPGA at Weeks 16 and 24 Comparing TAK-279 Against Apremilast
timeFrame: Baseline, Weeks 16 and 24
measure: Percentage of Participants Achieving a PGA of the Hands and/or Feet of Clear (0) or Almost Clear (1) with a >=2-Point Decrease From Baseline at Weeks 16 and 24 Comparing TAK-279 Against Apremilast
timeFrame: Baseline, Weeks 16 and 24
measure: Change from Baseline in SF-36 Version 2 Scores at Weeks 16 and 24 Comparing TAK-279 Against Apremilast
timeFrame: Baseline, Weeks 16 and 24
measure: Change from Baseline in the EQ-5D-5L Scores at Weeks 16 and 24 Comparing TAK-279 Against Apremilast
timeFrame: Baseline, Weeks 16 and 24
measure: Change from Baseline in the WPAI-PSO Scores at Weeks 16 and 24 Comparing TAK-279 Against Apremilast
timeFrame: Baseline, Weeks 16 and 24
measure: Percentage of Participants Achieving an sPGA of Clear (0) or Almost Clear (1) with a >=2-Point Decrease from Baseline at Weeks 24, 40, and 52 Comparing TAK-279 Against Apremilast
timeFrame: Baseline, Weeks 24, 40 and 52
measure: Percentage of Participants Achieving PASI-75 at Weeks 24, 40, and 52 Comparing TAK-279 Against Apremilast
timeFrame: Weeks 24, 40 and 52
measure: Percentage of Participants Achieving PASI-90 at Weeks 24, 40, and 52 Comparing TAK-279 Against Apremilast
timeFrame: Weeks 24, 40 and 52
measure: Number of Participants with Treatment-emergent Adverse Events (TEAEs) and Adverse Events of Special Interest (AESI)
timeFrame: Up to Week 56
measure: Number of Participants with Clinically Significant Vital Signs
timeFrame: Up to Week 56
measure: Number of Participants with Clinically Significant Laboratory Values
timeFrame: Up to Week 56
measure: Number of Participants with Clinically Significant Electrocardiogram (ECG) Findings
timeFrame: Up to Week 56
Other outcomes:
Locations:
city: Phoenix
country: United States
facility: Saguaro Dermatology Associates, LLC - Probity - PPDS
state: Arizona
city: Fountain Valley
country: United States
facility: First OC Dermatology - Fountain Valley
state: California
city: Fremont
country: United States
facility: Center for Dermatology Clinical Research
state: California
city: Los Angeles
country: United States
facility: UCLA University of California Los Angeles
state: California
city: Sacramento
country: United States
facility: UC Davis Dermatology Clinic
state: California
city: Coral Gables
country: United States
facility: Driven Research LLC
state: Florida
city: Fort Lauderdale
country: United States
facility: FXM Clinical Research Ft. Lauderdale, LLC
state: Florida
city: Hialeah
country: United States
facility: Direct Helpers Research Center
state: Florida
city: Miami
country: United States
facility: FXM Clinical Research Miami, LLC
state: Florida
city: Ocala
country: United States
facility: Renstar Medical Research -21 NE 1st Ave
state: Florida
city: Marietta
country: United States
facility: Marietta Dermatology & The Skin Cancer Center - Marietta
state: Georgia
city: Idaho Falls
country: United States
facility: Leavitt Clinical Research - 1542 Elk Creek Dr
state: Idaho
city: Rolling Meadows
country: United States
facility: Arlington Dermatology
state: Illinois
city: Indianapolis
country: United States
facility: Dawes Fretzin Clinical Research Group-7910 N Shadeland Ave
state: Indiana
city: Columbia
country: United States
facility: Kindred Hair & Skin Center - CAR
state: Maryland
city: Troy
country: United States
facility: Revival Research Corporation - Michigan - ClinEdge - PPDS
state: Michigan
city: Warren
country: United States
facility: Grekin Skin Institute
state: Michigan
city: Henderson
country: United States
facility: Henderson Clinical Trials
state: Nevada
city: Lebanon
country: United States
facility: Dartmouth Hitchcock Medical Center
state: New Hampshire
city: Portsmouth
country: United States
facility: ALLCUTIS Research, LLC.
state: New Hampshire
city: New York
country: United States
facility: Northwell Health Physician Partners Dermatology at Lake Success - BRANY - PPDS
state: New York
city: Cary
country: United States
facility: Accellacare of Cary
state: North Carolina
city: Bexley
country: United States
facility: Bexley Dermatology Research - Probity - PPDS
state: Ohio
city: Charleston
country: United States
facility: Clinical Research Center of the Carolinas, LLC
state: South Carolina
city: Murfreesboro
country: United States
facility: International Clinical Research-Tennessee LLC
state: Tennessee
city: Bellaire
country: United States
facility: Bellaire Dermatology Associates
state: Texas
city: San Antonio
country: United States
facility: Progressive Clinical Research PA - San Antonio
state: Texas
city: Kogarah
country: Australia
facility: St George Dermatology and Skin Cancer Center - Probity - PPDS
state: New South Wales
city: Benowa
country: Australia
facility: The Skin Center - Probity - PPDS
state: Queensland
city: Brisbane
country: Australia
facility: Veracity Clinical Research Pty Ltd
state: Queensland
city: Carlton
country: Australia
facility: Skin Health Institute Inc - Probity - PPDS
state: Victoria
city: East Melbourne
country: Australia
facility: Sinclair Dermatology-East Melbourne
state: Victoria
city: Parkville
country: Australia
facility: Alfred Health
state: Victoria
city: Parkville
country: Australia
facility: Royal Melbourne Hospital
state: Victoria
city: Calgary
country: Canada
facility: Beacon Dermatology - Probity - PPDS
state: Alberta
city: Surrey
country: Canada
facility: Enverus Medical Research - Probity - PPDS
state: British Columbia
city: Ajax
country: Canada
facility: CCA Medical Research - Probity - PPDS
state: Ontario
city: Barrie
country: Canada
facility: SimcoDerm Medical and Surgical Dermatology Centre - Probity - PPDS
state: Ontario
city: Etobicoke
country: Canada
facility: Kingsway Clinical Research - Probity - PPDS
state: Ontario
city: Guelph
country: Canada
facility: Guelph Dermatology Research - Probity - PPDS
state: Ontario
city: London
country: Canada
facility: Mediprobe Research Inc
state: Ontario
city: North Bay
country: Canada
facility: North Bay Dermatology Center - Probity - PPDS
state: Ontario
city: North York
country: Canada
facility: North York Research Inc. - Probity - PPDS
state: Ontario
city: Toronto
country: Canada
facility: Research Toronto - Probity - PPDS
state: Ontario
city: Beijing
country: China
facility: Peking University People's Hospital
state: Beijing
city: Beijing
country: China
facility: Beijing Friendship Hospital, Capital Medical University - PPDS
state: Beijing
city: Beijing
country: China
facility: Peking University Third Hospital
state: Beijing
city: Beijing
country: China
facility: Beijing Tongren Hospital, Capital Medical University
state: Beijing
city: Chongqing
country: China
facility: The First Affiliated Hospital of Chongqing Medical University
state: Chongqing
city: Fuzhou
country: China
facility: The First Affiliated Hospital of Fujian Medical University
state: Fujian
city: Guangzhou
country: China
facility: Dermatology Hospital of Southern Medical University
state: Guangdong
city: Guangzhou
country: China
facility: Sun Yat-sen Memorial Hospital, Sun Yat-sen University
state: Guangdong
city: Guangzhou
country: China
facility: Zhujiang Hospital of Southern Medical University
state: Guangdong
city: Shenzhen
country: China
facility: The University of Hong Kong - Shenzhen Hospital
state: Guangdong
city: Shijiazhuang
country: China
facility: The First Hospital of Hebei Medical University
state: Hebei
city: Wuhan
country: China
facility: Renmin Hospital of Wuhan University
state: Hubei
city: Wuhan
country: China
facility: Union Hospital Tongji Medical College Huazhong University of Science and Technology
state: Hubei
city: Shenyang
country: China
facility: The First Hospital of China Medical University
state: Liaoning
city: Yinchuan
country: China
facility: General Hospital of Ningxia Medical University
state: Ningxia
city: Xian
country: China
facility: The Second Affiliated Hospital of Xi'an Jiaotong University
state: Shaanxi
city: Jinan
country: China
facility: Shandong Provincial Hospital
state: Shandong
city: Shanghai
country: China
facility: Shanghai Skin Disease Hospital
state: Shanghai
city: Hangzhou
country: China
facility: Zhejiang Provincial People's Hospital
state: Zhejiang
city: Wenzhou
country: China
facility: The 1st Affiliated Hospital of Wenzhou Medical University - Nanbaixiang Campus
state: Zhejiang
city: Blankenfelde-Mahlow
country: Germany
facility: Hautarztpraxis Mahlow
state: Brandenburg
city: Oldenburg (Oldenburg)
country: Germany
facility: Klinikum Oldenburg AöR
state: Niedersachsen
city: Münster
country: Germany
facility: Universitätsklinikum Münster
state: Nordrhein-Westfalen
city: Lübeck
country: Germany
facility: Universitätsklinikum Schleswig-Holstein - Campus Lübeck
state: Schleswig-Holstein
city: L'aquila
country: Italy
facility: ASL 1 L'Aquila - Presidio Ospedaliero San Salvatore
state: Abruzzo
city: Napoli
country: Italy
facility: Azienda Ospedaliera Universitaria Luigi Vanvitelli - Via Pansini 5
state: Campania
city: Genova
country: Italy
facility: IRCCS Az. Osp. Universitaria San Martino- IST
state: Liguria
city: Milano
country: Italy
facility: Fondazione IRCCS Cà Granda Ospedale Maggiore Policlinico -Via Pace 9
state: Lombardia
city: Rozzano
country: Italy
facility: IRCCS Istituto Clinico Humanitas
state: Lombardia
city: San Donato Milanese
country: Italy
facility: IRCCS Policlinico San Donato
state: Lombardia
city: Catania
country: Italy
facility: Presidio Ospedaliero Gaspare Rodolico
state: Sicilia
city: Firenze
country: Italy
facility: Azienda Usl Toscana Centro - Firenze
state: Toscana
city: Nagoya-Shi
country: Japan
facility: Nagoya City University Hospital
state: Aiti
city: Obihiro-Shi
country: Japan
facility: Takagi Dermatological Clinic
state: Hokkaidô
city: Sapporo-Shi
country: Japan
facility: JR Sapporo Hospital
state: Hokkaidô
city: Sapporo-Shi
country: Japan
facility: Medical Corporation Kojinkai Sapporo Skin Clinic
state: Hokkaidô
city: Fukuoka-Shi
country: Japan
facility: Fukuoka University Hospital
state: Hukuoka
city: Kagoshima-Shi
country: Japan
facility: Saruwatari Dermatology Clinic
state: Kagosima
city: Isehara-Shi
country: Japan
facility: Tokai University Hospital
state: Kanagawa
city: Itabashi-Ku
country: Japan
facility: Teikyo University Hospital
state: Tokyo
city: Shinjuku-Ku
country: Japan
facility: Tokyo Medical University Hospital
state: Tokyo
city: Shinjuku-Ku
country: Japan
facility: JCHO Tokyo Yamate Medical Center
state: Tokyo
city: Sumida-Ku
country: Japan
facility: Tokyo Teishin Hospital
state: Tokyo
city: Shimotsuke-Shi
country: Japan
facility: Jichi Medical University Hospital
state: Totigi
city: Kumamoto
country: Japan
facility: Ohyama Dermatology Clinic
city: Sakai-Shi
country: Japan
facility: Dermatology and Ophthalmology Kume Clinic
state: Ôsaka
city: Seo-Gu
country: Korea, Republic of
facility: Pusan National University Hospital
state: Busan Gwangyeogsi
city: Daejeon
country: Korea, Republic of
facility: Chungnam National University Hospital
state: Daejeon Gwang'yeogsi
city: Savannah
country: Korea, Republic of
facility: Georgia Skin and Cancer Clinic
state: Georgia
city: Gwangju
country: Korea, Republic of
facility: Chosun University Hospital
state: Gwangju Gwang'yeogsi
city: Bucheon-si
country: Korea, Republic of
facility: The Catholic University of Korea, Bucheon St. Mary's Hospital
state: Gyeonggido
city: Bundang-Gu Seongnam-Si
country: Korea, Republic of
facility: CHA Bundang Medical Center, CHA University - PPDS
state: Gyeonggido
city: Bundang-Gu
country: Korea, Republic of
facility: Seoul National University Bundang Hospital
state: Gyeonggido
city: Gwangjin-Gu
country: Korea, Republic of
facility: Konkuk University Medical Center
state: Seoul Teugbyeolsi
city: Jongno-Gu
country: Korea, Republic of
facility: Seoul National University Hospital
state: Seoul Teugbyeolsi
city: Seocho-Gu
country: Korea, Republic of
facility: The Catholic University of Korea, Seoul St. Mary's Hospital
state: Seoul Teugbyeolsi
city: Seoul
country: Korea, Republic of
facility: Soon Chun Hyang University Hospital Seoul
state: Seoul Teugbyeolsi
city: Seoul
country: Korea, Republic of
facility: Ewha Womans University Seoul Hospital
state: Seoul Teugbyeolsi
city: Seoul
country: Korea, Republic of
facility: Kyung Hee University Hospital
city: Seoul
country: Korea, Republic of
facility: Chung-Ang University Hospital
city: Wonju
country: Korea, Republic of
facility: Yonsei University Wonju Severance Christian Hospital
city: Wroclaw
country: Poland
facility: Cityclinic Przychodnia Lekarsko Psychologiczna Matusiak Spółka Partnerska
state: Dolnoslaskie
city: Lublin
country: Poland
facility: Clinical Best Solutions - Lublin
state: Lubelskie
city: Lódz
country: Poland
facility: Dermoklinika-Centrum Medyczne s.c
state: Lódzkie
city: Nadarzyn
country: Poland
facility: Rheumatology Clinic NZOZ Lecznica MAK-MED
state: Mazowieckie
city: Warsaw
country: Poland
facility: Klinika Reuma Park sp . zoo Sp.k.
state: Mazowieckie
city: Warsaw
country: Poland
facility: Klinika Ambroziak - Kosiarzy 9A
state: Mazowieckie
city: Warszawa
country: Poland
facility: Clinical Best Solutions - Warszawa
state: Mazowieckie
city: Warszawa
country: Poland
facility: MICS Centrum Medyczne Warszawa - MICS - PPDS
state: Mazowieckie
city: Warszawa
country: Poland
facility: High-Med Przychodnia Specjalistyczna
state: Mazowieckie
city: Bialystok
country: Poland
facility: ClinicMed Daniluk, Nowak Spólka Komandytowa
state: Podlaskie
city: Gdansk
country: Poland
facility: Copernicus Podmiot Leczniczy Sp. z o.o. - al. Jana Pawla II 50
state: Pomorskie
city: Gdańsk
country: Poland
facility: AES - DRS - Synexus Polska Sp. z o.o. Oddzial w Gdansku
state: Pomorskie
city: Gdynia
country: Poland
facility: Derm-art
state: Pomorskie
city: Katowice
country: Poland
facility: Centrum Medyczne Katowice - PRATIA - PPDS
state: Slaskie
city: Poznań
country: Poland
facility: AES - DRS - Synexus Polska Sp. z o.o. Oddzial w Poznaniu
state: Wielkopolskie
city: Szczecin
country: Poland
facility: Twoja Przychodnia SCM - Slowackiego
state: Zachodniopomorskie
city: Bydgoszcz
country: Poland
facility: Centrum Medyczne Bydgoszcz- PRATIA - PPDS
city: Krakow
country: Poland
facility: Centrum Medyczne PROMED
city: Lodz
country: Poland
facility: Uniwersytecki Szpital Kliniczny im. WAM - Centralny Szpital Weteranow-Lodz-ul. Plac J. Hallera 1
city: Hsinchu
country: Taiwan
facility: National Taiwan University Hospital - Hsin-Chu Branch
city: Kaohsiung City
country: Taiwan
facility: Kaohsiung Veterans General Hospital
city: New Taipei City
country: Taiwan
facility: Taipei Medical University Shuang Ho Hospital
city: Tainan
country: Taiwan
facility: National Cheng Kung University Hospital
city: Taipei City
country: Taiwan
facility: Taipei Veterans General Hospital
city: Taipei
country: Taiwan
facility: Mackay Memorial Hospital-Taipei branch
city: Taoyuan City
country: Taiwan
facility: Chang Gung Memorial Hospital, Linkou
city: Zhong Zheng Qu
country: Taiwan
facility: National Taiwan University Hospital
Study officials:
affiliation: Takeda
name: Study Director
role: STUDY_DIRECTOR
References: